DeepMed Research

THE UNIVERSITY OF QUEENSLAND

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1909-01-01

Employees: 5K

Market Cap: -

Website: http://www.uq.edu.au

Clinical Trials

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis

Phase 2

Completed

Conditions: Ataxia Telangiectasia

Interventions: Dietary Supplement: Triheptanoin

First Posted Date: 2020-08-14

Last Posted Date: 2023-07-20

Lead Sponsor: The University of Queensland

Target Recruit Count: 30

Registration Number: NCT04513002

Locations: 🇦🇺
Queensland Children's Hospital, Brisbane, Queensland, Australia

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Phase 3

Completed

Conditions: Respiratory Viral Infection
Covid19

Interventions: Drug: Broncho-Vaxom®

First Posted Date: 2020-08-03

Last Posted Date: 2022-03-09

Lead Sponsor: The University of Queensland

Target Recruit Count: 59

Registration Number: NCT04496245

Locations: 🇦🇺
The Prince Charles Hospital, Brisbane, Queensland, Australia
🇦🇺
The Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺
Queensland Children's Hospital, South Brisbane, Queensland, Australia

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Phase 1

Completed

Conditions: SARS-CoV2
Covid19

Interventions: Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
Other: Placebo

First Posted Date: 2020-08-03

Last Posted Date: 2024-05-02

Lead Sponsor: The University of Queensland

Target Recruit Count: 216

Registration Number: NCT04495933

Locations: 🇦🇺
Nucleus Network Brisbane (Q-Pharm Pty Ltd), Herston, Queensland, Australia

Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities

Not Applicable

Terminated

Conditions: Gastroenteritis
Influenza
COVID

Interventions: Behavioral: Newsfeed function
Behavioral: Gamification

First Posted Date: 2020-05-06

Last Posted Date: 2021-03-09

Lead Sponsor: The University of Queensland

Target Recruit Count: 34

Registration Number: NCT04377165

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Phase 2

Recruiting

Conditions: Pulmonary Disease Due to Mycobacteria (Diagnosis)

Interventions: Drug: Amikacin
Drug: Tigecycline
Drug: Imipenem
Drug: Cefoxitin
Drug: Linezolid
Drug: Azithromycin
Drug: co-trimoxazole
Drug: Clarithromycin
Drug: Clofazimine
Drug: Doxycycline
Drug: Moxifloxacin
Drug: Ethambutol
Drug: Bedaquiline
Drug: Rifabutin

First Posted Date: 2020-03-17

Last Posted Date: 2024-12-11

Lead Sponsor: The University of Queensland

Target Recruit Count: 300

Registration Number: NCT04310930

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations

Testing the Efficacy of the Ability School Engagement Partnership Program (ASEP)

Not Applicable

Conditions: Welfare Dependence
School Attendance
Antisocial Behavior

Interventions: Behavioral: Ability School Engagement Program Conference

First Posted Date: 2020-02-24

Last Posted Date: 2020-03-09

Lead Sponsor: The University of Queensland

Target Recruit Count: 753

Registration Number: NCT04281966

Locations: 🇦🇺
The University of Queensland, Brisbane, Queensland, Australia

Gonorrhoea Resistance Assessment by Nucleic Acid Detection (GRANDII)

Not Applicable

Active, not recruiting

Conditions: Gonorrhea
Drug Resistance, Microbial
Antimicrobial Stewardship

Interventions: Other: Resistance guided treatment for gonorrhoea infection

First Posted Date: 2020-02-13

Last Posted Date: 2022-11-28

Lead Sponsor: The University of Queensland

Target Recruit Count: 1626

Registration Number: NCT04268342

Locations: 🇦🇺
University of Queensland, Brisbane, Queensland, Australia

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

Phase 3

Withdrawn

Conditions: Bacteremia Caused by Gram-Negative Bacteria

Interventions: Drug: Ceftolozane-Tazobactam
Drug: Meropenem

First Posted Date: 2020-01-23

Last Posted Date: 2022-05-19

Lead Sponsor: The University of Queensland

Registration Number: NCT04238390

Locations: 🇦🇺
Sir Charles Gairdner, Perth, Western Australia, Australia
🇦🇺
Fiona Stanley Hospital, Perth, Western Australia, Australia
🇸🇦
King Abdulaziz Medical City, Riyadh, Saudi Arabia

and more 26 locations

Vascular Access Outcome Measure for Function: a vaLidation Study In haemoDialysis

Completed

Conditions: Vascular Access Complication
Hemodialysis Access Failure (Disorder)

First Posted Date: 2019-05-31

Last Posted Date: 2024-05-10

Lead Sponsor: The University of Queensland

Target Recruit Count: 702

Registration Number: NCT03969225

Locations: 🇨🇭
Ospedale Regionale di Lugano, Lugano, Switzerland
🇬🇧
Sheffield Teaching Hospital, Sheffield, United Kingdom
🇫🇷
Centre Hospitalier Régional Universitaire de Tours, Tours, France

and more 7 locations

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Phase 2

Completed

Conditions: Bloodstream Infections

Interventions: Other: Best Available Therapy
Drug: Cefiderocol

First Posted Date: 2019-03-11

Last Posted Date: 2024-02-13

Lead Sponsor: The University of Queensland

Target Recruit Count: 513

Registration Number: NCT03869437

Locations: 🇸🇬
National University Hospital Singapore, Singapore, Singapore
🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy